Compare ResMed Inc. (RMD) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Uranium Energy Corp — how do they compare? ResMed Inc. trades at $194.03 (market cap $28.81B), while Uranium Energy Corp trades at $9.55 (market cap $4.65B). The key difference: ResMed Inc. is far larger — about 6.2× Uranium Energy Corp's market cap, and ResMed Inc. pays a 1.21% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| RMD | UEC | |
|---|---|---|
Market Cap | $28.81B | $4.65B |
Sector | Health | Energy |
52-Week High | $293.73 | $20.14 |
52-Week Low | $182.82 | $8.00 |
Enterprise Value | $27.99B | $4.16B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Uranium Energy Corp (UEC) trades at $9.40, up 1.29% today, amid bearish technical signals and challenging fundamentals. The stock shows negative profitability with a net income margin of -513.24% and has missed earnings estimates in two of the last three quarters. Recent news highlights operational pressures and strategic positioning in the uranium sector, with analyst sentiment remaining largely positive despite financial headwinds.
The outlook for UEC hinges on execution of its in-situ recovery ramp-up and uranium sales timing. Investment opportunity lies in its debt-free balance sheet and $794 million liquidity, but risks include persistent losses, high valuation multiples, and reliance on uranium price recovery. Wall Street maintains a buy-heavy consensus, suggesting long-term potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
